blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1054881

EP1054881 - NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.06.2009
Database last updated on 22.01.2025
Most recent event   Tooltip07.10.2011Lapse of the patent in a contracting state
New state(s): FR		published on 09.11.2011  [2011/45]
Applicant(s)For all designated states
BAYER CORPORATION
100 Bayer Road
Pittsburgh, PA 15205-9741 / US
[2008/31]
Former [2000/48]For all designated states
Bayer Corporation
100 Bayer Road
Pittsburgh, PA 15205-9741 / US
Inventor(s)01 / LADOUCEUR, Gaetan, H.
31 Stone Ridge Lane
Branford, CT 06405 / US
02 / CONNELL, Richard, D.
68 Lobsterback Road
Trumbull, CT 06611 / US
03 / BARYZA, Jeremy
Apartment 1, 22 Cottage Street
New Haven, CT 06511 / US
04 / CAMPBELL, Ann-Marie
69 Lynn Drive
Monroe, CT 06468 / US
05 / LEASE, Timothy, G.
74 Christopher Lane
Guilford, CT 06437 / US
06 / COOK, James, H.
174 Young Street
East Hampton, CN 06424 / US
[2000/48]
Representative(s)Burkert, Frank, et al
Bayer Schering Pharma Aktiengesellschaft
Law and Patents
Patents and Licensing
Building Q 18
51368 Leverkusen / DE
[N/P]
Former [2009/26]Burkert, Frank, et al
Bayer HealthCare AG CAO Law and Patents/Patents and Licensing
51368 Leverkusen / DE
Former [2000/48]Burkert, Frank, et al
Bayer AG Konzernbereich RP Patente und Lizenzen
51368 Leverkusen / DE
Application number, filing date98958070.917.11.1998
[2000/48]
WO1998US24627
Priority number, dateUS1997099458519.12.1997         Original published format: US 994585
[2000/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9932475
Date:01.07.1999
Language:EN
[1999/26]
Type: A1 Application with search report 
No.:EP1054881
Date:29.11.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 01.07.1999 takes the place of the publication of the European patent application.
[2000/48]
Type: B1 Patent specification 
No.:EP1054881
Date:30.07.2008
Language:EN
[2008/31]
Search report(s)International search report - published on:EP01.07.1999
ClassificationIPC:C07D311/58, A61K31/35, C07D405/12, C07D405/14, C07D471/04
[2000/48]
CPC:
C07D405/12 (EP); A61P1/00 (EP); A61P1/04 (EP);
A61P25/00 (EP); A61P25/24 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/08 (EP); A61P3/10 (EP);
A61P43/00 (EP); A61P9/10 (EP); C07D311/58 (EP);
C07D405/14 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/48]
Extension statesLT19.07.2000
LV19.07.2000
RO19.07.2000
SI19.07.2000
TitleGerman:NEUE SULFONAMID-SUBSTITUIERTE CHROMAN-DERIVATE VERWENDBAR ALS BETA 3 ADRENOREZEPTOR AGONISTEN[2000/48]
English:NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS[2000/48]
French:NOUVEAUX DERIVES DE CHROMANE A SULFAMIDE SUBSTITUE UTILISES COMME AGONISTES BETA-3 ADRENORECEPTEURS[2004/49]
Former [2000/48]NOUVEAUX DERIVES DE CHROMANE A SULFAMIDE SUBSTITUE UTILISES COMME AGONISTES $g(b)3-ADRENORECEPTEURS
Entry into regional phase19.07.2000National basic fee paid 
19.07.2000Designation fee(s) paid 
19.07.2000Examination fee paid 
Examination procedure29.06.1999Request for preliminary examination filed
International Preliminary Examining Authority: US
19.07.2000Examination requested  [2000/48]
31.07.2003Despatch of a communication from the examining division (Time limit: M06)
05.02.2004Reply to a communication from the examining division
19.03.2004Despatch of a communication from the examining division (Time limit: M06)
16.09.2004Reply to a communication from the examining division
25.10.2004Communication of intention to grant the patent
04.03.2005Fee for grant paid
04.03.2005Fee for publishing/printing paid
Opposition(s)06.05.2009No opposition filed within time limit [2009/28]
Fees paidRenewal fee
30.11.2000Renewal fee patent year 03
30.11.2001Renewal fee patent year 04
02.12.2002Renewal fee patent year 05
01.12.2003Renewal fee patent year 06
30.11.2004Renewal fee patent year 07
30.11.2005Renewal fee patent year 08
30.11.2006Renewal fee patent year 09
30.11.2007Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT30.07.2008
BE30.07.2008
CY30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
SE30.10.2008
GR31.10.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
LU17.11.2008
CH30.11.2008
FR30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
[2011/45]
Former [2011/25]AT30.07.2008
BE30.07.2008
CY30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
SE30.10.2008
GR31.10.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
LU17.11.2008
CH30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
Former [2010/44]AT30.07.2008
BE30.07.2008
CY30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
SE30.10.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
LU17.11.2008
CH30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
Former [2010/28]AT30.07.2008
BE30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
SE30.10.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
LU17.11.2008
CH30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
Former [2010/19]AT30.07.2008
BE30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
SE30.10.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
CH30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
Former [2010/06]AT30.07.2008
BE30.07.2008
DK30.07.2008
FI30.07.2008
IT30.07.2008
NL30.07.2008
ES10.11.2008
GB17.11.2008
IE17.11.2008
CH30.11.2008
LI30.11.2008
MC30.11.2008
PT30.12.2008
Former [2009/30]AT30.07.2008
BE30.07.2008
DK30.07.2008
FI30.07.2008
NL30.07.2008
ES10.11.2008
MC30.11.2008
PT30.12.2008
Former [2009/19]AT30.07.2008
BE30.07.2008
DK30.07.2008
FI30.07.2008
NL30.07.2008
ES10.11.2008
PT30.12.2008
Former [2009/15]AT30.07.2008
FI30.07.2008
NL30.07.2008
ES10.11.2008
PT30.12.2008
Former [2009/12]FI30.07.2008
NL30.07.2008
ES10.11.2008
PT30.12.2008
Former [2009/09]NL30.07.2008
ES10.11.2008
PT30.12.2008
Cited inInternational search[A]EP0091749  (BEECHAM GROUP PLC [GB]) [A] 1-24 * the whole document *;
 [A]EP0611003  (MERCK & CO INC [US]) [A] 1-24 * the whole document *;
 [A]WO9529159  (MERCK & CO INC [US], et al) [A] 1-24 * the whole document *;
 [X]US5663194  (MEWSHAW RICHARD E [US]) [X] 7,8* claims 1,6,9 *;
 [A]FR2746395  (ADIR [FR]) [A] 1-24 * the whole document *;
 [A]EP0801060  (PFIZER [US]) [A] 1-24 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.